menu
    • menu
    [{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Reyon Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"||Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reyon Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Teicoplanin

    Menu

    Teicoplanin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Teicoplanin in CDAD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 01, 2019

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radboud University Medical Center

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            Radboud University Medical Center

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TDM-optimized Teicoplanin Dosing Versus Standard of Care

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 22, 2023

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inhaled Teicoplanin Completed Phase 1 Clinical Trial in Cystic Fibrosis

                            Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

                            Product Name : Teicoplanin Sandoz

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Reyon Pharmaceutical Co., Ltd

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            Reyon Pharmaceutical Co., Ltd

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin,Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            REYON's Teicoplanin and Arbekacin Enter Preclinical Trials for COVID-19

                            Details : Teicoplanin is a glycopeptide antibiotic, which is being evaluated in combination with arbekacin sulfate for the treatment of covid-19.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 06, 2020

                            Lead Product(s) : Teicoplanin,Arbekacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

                            Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

                            Product Name : Teicoplanin Sandoz

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed

                            Neupharma

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Sintesi Research Srl | Evotec | Pari

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis P...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 25, 2019

                            Lead Product(s) : Teicoplanin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Sintesi Research Srl | Evotec | Pari

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth